Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.
Xuejiao YinLiang TangFengjuan FanQinyue JiangChunyan SunHan YanPublished in: Cancer cell international (2018)
Due to the lack of consistent survival benefit, allo-SCT should not be considered as a standard of care for newly diagnosed and relapsed standard-risk MM patients. However, for patients with high-risk MM who have a poor long-term prognosis, allo-SCT may be a strong consideration in their initial course of therapy or in first relapse after chemotherapy, when the risk of disease progression may outweigh the transplant-related risks. A large number of prospective randomized controlled trials were needed to prove the benefits of these therapeutic options.
Keyphrases
- stem cell transplantation
- newly diagnosed
- multiple myeloma
- high dose
- end stage renal disease
- randomized controlled trial
- healthcare
- chronic kidney disease
- ejection fraction
- prognostic factors
- palliative care
- acute lymphoblastic leukemia
- free survival
- acute myeloid leukemia
- bone marrow
- squamous cell carcinoma
- low dose
- systematic review
- climate change
- quality improvement
- peritoneal dialysis
- mesenchymal stem cells
- clinical trial
- patient reported outcomes
- chronic pain
- cell therapy
- drug induced